Gonadorelin

Generic Name: Gonadorelin

Brand Names: Lutrepulse

Drug Type: Small Molecule

Chemical Formula: C_₅₅H_₇₅N_₁₇O_₁₃

CAS Number: 33515-09-2

Unique Ingredient Identifier: 9O7312W37G

Background: Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

Indication: For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.

Associated Conditions: -

Associated Therapies: Ovulation induction therapy

Clinical Trials

Recall by Genotype: Neuropeptide Stimulation

Phase 1

Terminated

Conditions: Reproductive Disorder

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2023-06-13

Last Posted Date: 2024-06-03

Lead Sponsor: Stephanie B. Seminara, MD

Target Recruit Count: 16

Registration Number: NCT05901467

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

Not yet recruiting

Conditions: Testosterone Deficiency
Metabolic Disturbance
Cardiovascular Diseases
Diabetes
Hypogonadism, Male
Androgen Deficiency
Metabolic Disease
Obesity
NAFLD
Prostate Cancer

Interventions: Drug: Testosterone
Drug: GnRH

First Posted Date: 2023-03-17

Last Posted Date: 2023-03-17

Lead Sponsor: Royal College of Surgeons, Ireland

Target Recruit Count: 60

Registration Number: NCT05773183

Locations: 🇮🇪
Beaumont Hospital, Dublin 9, Ireland

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

Not Applicable

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: Gonadorelin

First Posted Date: 2022-01-11

Last Posted Date: 2022-01-11

Lead Sponsor: Huashan Hospital

Target Recruit Count: 20

Registration Number: NCT05184374

Locations: 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Phase 4

Active, not recruiting

Conditions: Menopause
Estrogen Deficiency
Women
Aging

Interventions: Drug: GnRH antagonist

First Posted Date: 2021-09-27

Last Posted Date: 2024-03-21

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 55

Registration Number: NCT05057546

Locations: 🇺🇸
University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Phase 2

Recruiting

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2020-12-02

Last Posted Date: 2024-08-01

Lead Sponsor: Stephanie B. Seminara, MD

Target Recruit Count: 24

Registration Number: NCT04648969

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Bioenergetic Effects of Aging and Menopause (BEAM)

Phase 4

Recruiting

Conditions: Aging
Weight Gain
Obesity, Abdominal
Menopause

Interventions: Drug: GnRH antagonist
Drug: Placebo GnRH antagonist
Drug: Placebo estradiol
Drug: Estrogen Product

First Posted Date: 2019-08-02

Last Posted Date: 2023-12-18

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 57

Registration Number: NCT04043520

Locations: 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States

Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome

Phase 4

Conditions: Polycystic Ovary Syndrome
Ovulation Disorder
Infertility

Interventions: Drug: Gonadorelin
Drug: Clomiphene

First Posted Date: 2019-06-18

Last Posted Date: 2019-06-18

Lead Sponsor: RenJi Hospital

Target Recruit Count: 78

Registration Number: NCT03989024

Locations: 🇨🇳
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

Effects of Testosterone and Fat Utilization

Not Applicable

Completed

Conditions: Healthy
Volunteers

Interventions: Drug: GnRH antagonist
Drug: Aromatase Inhibitors
Drug: Testosterone gel

First Posted Date: 2017-09-21

Last Posted Date: 2017-09-21

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 13

Registration Number: NCT03289559

Hormonal Mechanisms of Sleep Restriction - Axis Study

Phase 1

Active, not recruiting

Conditions: Sleep Restriction

Interventions: Drug: Gonadorelin
Drug: Ganirelix
Drug: Ketoconazole Pill
Drug: Dexamethasone Injection
Drug: Corticorelin
Drug: Hydrocortisone Injection
Drug: Dexamethasone
Drug: Placebo oral capsule
Drug: Cosyntropin Injectable Product
Drug: Saline Solution
Drug: Recombinant Human Luteinizing Hormone
Drug: Saline Solution for Injection

First Posted Date: 2017-05-08

Last Posted Date: 2024-04-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT03142893

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: GnRH
Drug: Bicalutamide
Radiation: Salvage radiation
Drug: Abiraterone
Drug: Prednisone
Drug: Apalutamide

First Posted Date: 2017-05-05

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 345

Registration Number: NCT03141671

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy